Status:
WITHDRAWN
Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder
Lead Sponsor:
New York State Psychiatric Institute
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Obsessive-Compulsive Disorder
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this research study is to test how a medication called nabilone (Cesamet) affects neurocognitive processes involved in obsessive-compulsive disorder (OCD), including threat response, pr...
Detailed Description
The total time required for each participant is 4 visits, as outlined below: Visit 1: Screening, Questionnaires, and Orientation: During this visit potential participants will learn about the study p...
Eligibility Criteria
Inclusion
- Between 21-55 years of age
- Physically healthy and, if female, not pregnant
- Able to tolerate all study procedures
- Able to provide written informed consent to participate
- Right-handed
- Primary diagnosis of OCD
- Not taking psychotropic medications or other substances likely to interact with nabilone
Exclusion
- History of any significant medical condition that may increase the risk of participation
- Females who are pregnant or nursing
- Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation (e.g. lifetime psychosis or bipolar disorder)
- Current substance use disorder
- Positive urine toxicology or alcohol breathalyzer
- Any history of adverse reaction to a cannabinoid
- History of receiving cognitive behavior or exposure-based psychotherapy in the past 3 months
- History of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)
- History of claustrophobia or unable to tolerate confined spaces like an MRI
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04880278
Start Date
March 1 2022
End Date
May 8 2024
Last Update
May 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032